Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example Group: SGLT2 inhibitors Group in Adults with type 2 diabetes

Page standards status: Informative

Generated Narrative: Group 236949

version: 70; Last updated: 2025-03-20 18:40:09+0000

Profile: ExposureGroup

Artifact Author: Computable Publishing®: MAGIC-to-FEvIR Converter:

RelatesTo

  • type: part-of
  • targetReference: MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report)

url: https://fevir.net/resources/Group/236949

identifier: FEvIR Object Identifier/https://fevir.net/FOI/236949, FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-intervention-group-MAGIC-5288-j1Wqrn-intervention-85394-I-85798

title: SGLT2 inhibitors Group in Adults with type 2 diabetes

status: Active

publisher: Computable Publishing LLC

contact: support@computablepublishing.com

description:

Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors

UseContexts

-CodeValue[x]
*Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication: Evidence CommunicationExposureGroup

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

type: Person

membership: Enumerated

combinationMethod: All of

characteristic

code: Member of

value: Adults with type 2 diabetes and CVD and CKD

exclude: false

description:

inclusion in Adults with type 2 diabetes

characteristic

code: Exposed to

value: Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors

exclude: false

description:

received SGLT2 inhibitors